• Device Performance and Benefits evaluated through the Oxford Shoulder Score outcome measure. [ Time Frame: Out to 10 years ]
  The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Oxford Shoulder Score (OSS). The OSS is a 12 item questionnaire, each with 5 potential answers. Patients rate their symptoms from 1 (minimal symptoms) to 5 (severe symptoms). The combined total gives a minimum score of 12 and a maximum of 60. Higher scores in the OSS imply worse functionality.
• Device Performance and Benefits evaluated through the Patient Assessment Questionnaire. [ Time Frame: Out to 10 years ]
  The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Patient Assessment Questionnaire where adverse events and/or complications (yes or no), patient's activity level with regard to operative side, based on the UCLA Activity Score(wholly inactive 10, mostly inactive 9, sometimes participates in mild activities 8, regularly participates in mild activities 7, sometimes participates in moderate activities 6, regularly participates in moderate activities 5, regularly participates in active events 4, regularly participates in very active events 3, sometimes participates in impact sports 2, regularly participates in impact sports 1, or not recorded), and the Reported Score if Individual Scores are not available of the Oxford Shoulder Score. The UCLA Activity score rating is from 10 being the best outcome score, and 1 being the worst.

• Device Performance and Benefits evaluated through the ASES outcome measure [ Time Frame: Out to 10 years ]
  The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).
• Device Performance and Benefits evaluated through the UCLA activity score [ Time Frame: Out to 10 years ]
  The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,2,3,5,7 and 10 years*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinical history. Therefore, a prospective aspect to the study will be utilized in order to collect long-term data.

The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to either implant or instrumentation should be specified.

The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).

*The most recent available data will be used. If any of the listed time points are not available, data will be used from last available time point and follow-up will move forward at the closest available time point.

• Shoulder Pain
• Shoulder Injuries
• Shoulder Fractures
• Shoulder Disease
• Shoulder Arthritis

Inclusion Criteria:

• Patient must be 18 years of age or older.

Patient must have undergone the primary or revision shoulder arthroplasty with the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads for a cleared indication. Cleared indications include the following:

o non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis, rheumatoid arthritis, revision where other devices or treatments have failed, correction of functional deformity, fractures of the proximal humerus where other methods of treatment are deemed inadequate, and difficult clinical management problems including cuff arthroplasty where other treatment methods may not be suitable.

Patients must have the ability and willingness to follow instructions, including control of weight and activity levels.

Patients must have a good nutritional state. Patients must have reached full skeletal maturity and have a functional deltoid muscle.

Exclusion Criteria:

• Absolute contraindications include infection, sepsis, and osteomyelitis.

Relative contraindications include:

Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions Osteoporosis Metabolic disorders which may impair bone formation Osteomalacia Distant foci of infections which may spread to the implant site Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram Patient is a prisoner. Patient is a current alcohol or drug abuser. Patient is known to be pregnant or breastfeeding. Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent